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Abstract
Background: The vasculitides are a group of rare diseases with different manifestations and outcomes. New
therapeutic options have led to the need for long-term registries. The Rheumatic Diseases Portuguese Register,
Reuma.pt, is a web-based electronic clinical record, created in 2008, which currently includes specific modules for
12 diseases and > 20,000 patients registered from 79 rheumatology centres. On October 2014, a dedicated module
for vasculitis was created as part of the European Vasculitis Society collaborative network, enabling prospective
collection and central storage of encrypted data from patients with this condition. All Portuguese rheumatology
centres were invited to participate. Data regarding demographics, diagnosis, classification criteria, assessment tools,
and treatment were collected. We aim to describe the structure of Reuma.pt/vasculitis and characterize the patients
registered since its development.
Results: A total of 687 patients, with 1945 visits, from 13 centres were registered; mean age was 53.4 ± 19.3 years at
last visit and 68.7% were females. The most common diagnoses were Behçet’s disease (BD) (42.5%) and giant cell
arteritis (GCA) (17.8%). Patients with BD met the International Study Group criteria and the International Criteria for
BD in 85.3 and 97.2% of cases, respectively. Within the most common small- and medium-vessel vasculitides
registered, median [interquartile range] Birmingham Vasculitis Activity Score (BVAS) at first visit was highest in
patients with ANCA-associated vasculitis (AAV) (17.0 [12.0]); there were no differences in the proportion of patients
with AAV or polyarteritis nodosa who relapsed (BVAS≥1) or had a major relapse (≥1 major BVAS item) during
prospective assessment (p = 1.00, p = 0.479). Biologic treatment was prescribed in 0.8% of patients with GCA, 26.7%
of patients with AAV, and 7.6% of patients with BD. There were 34 (4.9%) deaths reported.
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Conclusions: Reuma.pt/vasculitis is a bespoke web-based registry adapted for routine care of patients with this
form of rare and complex diseases, allowing an efficient data-repository at a national level with the potential to link
with other international databases. It facilitates research, trials recruitment, service planning and benchmarking.
Keywords: Rare diseases, Vasculitis, Patient registries, Database management systems, Patient reported outcome
measures
Introduction
The vasculitides are a group of relatively uncommon
and complex diseases. The increased clinical trial activity
and new therapeutic options for patients with vasculitis
have led to the development of long-term specific regis-
tries for this condition [1, 2].
The Rheumatic Diseases Portuguese Register, Reu-
ma.pt, was created in June 2008 with the aim of pro-
spectively record clinical data and treatment adverse
effects of patients from all Portuguese rheumatology de-
partments [3–5]. It has been available as a web based
online system since 2012 (www.reuma.pt) and currently
includes specific modules for twelve different groups of
rheumatic diseases (autoinflammatory syndromes, early
arthritis, juvenile idiopathic arthritis, myositis, osteoarth-
ritis, psoriatic arthritis, rheumatoid arthritis, sclero-
derma, Sjögren’s syndrome, spondyloarthritis, systemic
lupus erythematosus and vasculitis) in Portuguese and
English language. Over 20,000 patients and 170,000 visits
have been registered, up to December 2018, by 79
national and international rheumatology centres. On
October 2014, Reuma.pt launched a dedicated module
to register patients with vasculitis. The variables in-
cluded were chosen based on other pre-existing Euro-
pean registries, particularly UKIVAS (UK and Ireland
Vasculitis Registry) [6], as part of the European Vascu-
litis Society (EUVAS) collaborative network with the
long-term goal of having compatible registries capable of
analysing important outcomes in a larger scale [7, 8].
Our aim is to describe the structure of Reuma.pt/vas-
culitis and give a brief overview on the characteristics of
patients registered since its development.
Methods
Description and contents
Reuma.pt works as an electronic medical record, which
enables prospective collection and central storage of
encrypted data. The database information security was
approved by the Portuguese National Commission for
Data Protection and the ethics committees of the partici-
pating institutions. Registered patients are required to
sign an informed consent. All identifiable data is
encrypted, only accessible through an individual pass-
word attributed to clinicians, who can only visualize data
related to their centre. Reuma.pt is managed by the
Portuguese Society of Rheumatology and has similar
structured modules for each disease. Reuma.pt users can
work indifferently in Portuguese and English, as the all
system is bilingual. A detailed description of its general
design and data management has been published else-
where [3].
The Reuma.pt/vasculitis displays a tree format table of
contents on the left hand side (Fig. 1) where standard
items, equal to all Reuma.pt modules, and disease spe-
cific items are collected. All sections highlighted in red
are mandatory for completion at each patient visit.
Standard items include patient identification, biobank
code for linkage, informed consent status, demographics
(date of birth, gender, ethnicity, marital status, education
and working status), date of disease onset and diagnosis,
past medical history, previous surgeries, smoking and al-
cohol habits, vaccination, screening for tuberculosis,
diagnostic test results, quality of life assessments (Short
form 36 [SF-36], EuroQol-5D [EQ-5D], Functional As-
sessment of Chronic Illness Therapy [FACIT] Fatigue
Scale, and Hospital Anxiety and Depression Scale
[HADS]), treatment history and report of adverse
advents (which is electronically linked to the National
Authority of Medicines and Health Products -
INFARMED). In addition, patients have their own dedi-
cated area that can also be accessed online to complete
the patient reported outcomes before the medical visit.
Within the disease specific items, the 2012 Revised
International Chapel Hill Consensus Conference
Nomenclature of Vasculitides [9] is used to select the
diagnosis subtype (Fig. 1, section 1), according to which
a possible classification criteria set is available for com-
pletion: the 1990 American College of Rheumatology
(ACR) classification criteria for giant cell arteritis (GCA,
former temporal arteritis) [10], Takayasu’s arteritis
(TAK) [11], polyarteritis nodosa (PAN) [12], granuloma-
tosis with polyangiitis (GPA, former Wegener’s granulo-
matosis) [13], eosinophilic granulomatosis with
polyangiitis (EGPA, former Churg-Strauss Syndrome)
[14] and IgA vasculitis (IgAV, former Henoch–Schönlein
purpura) [15]; the 1984 Lanham criteria also for EGPA
[16]; the 2004 American Heart Association Diagnostic
Criteria for Kawasaki disease (KD) [17]; the 1990 Inter-
national Study Group criteria and the 2006 and 2013
International Criteria for Behçet’s disease (BD) [18–20]
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and the 2011 preliminary classification criteria for cryo-
globulinaemic vasculitis (CV) [21]. After the completion
of the criteria an automatic sentence appears at the bot-
tom of the screen informing the submitting physician if
the patients meets the criteria (example for GCA in Sup-
plementary Fig 1). We expect to update these criteria
after the results from the DCVAS study (Diagnostic and
Classification Criteria for Vasculitis) [22] are published.
Additional information regarding symptoms and signs,
which may have not been collected in the classification
criteria, are available for completion in a different sec-
tion - clinical features section - with automatic export-
ation of data to equivalent items in the first Birmingham
Vasculitis Activity Score (BVAS) assessment (Fig. 1, sec-
tion 6). Moreover, in the general clinical data section
(Fig. 1, section 2), specific medications and illicit drugs
known to be associated with the development of vascu-
litis, were extracted from the DCVAS case report form
(CRF) and are inquired in this registry. Given the items
collected in the DCVAS CRF were revised and agreed
upon in a EUVAS meeting in 2010, they work as
references for data collection in some European regis-
tries (e.g. UKIVAS). Data on specific vasculitis immun-
ology tests (anti-neutrophil cytoplasmic antibodies
[ANCA], anti–glomerular basement membrane [anti-
GBM] and cryoglobulins), genetics (human leukocyte
antigen [HLA]-B51) (Fig. 1, section 3) and biopsy fea-
tures (based on the DCVAS CRF) are also collected. Re-
garding specific disease assessments: for prognosis the
Five Factor score (FFS) - original and revised - is col-
lected for ANCA-associated vasculitides (AAV) and
PAN (Fig. 1, section 4) [23, 24] and the cardiovascular
risk score is available to estimate risk in GPA and micro-
scopic polyangiitis (MPA) [25] (Fig. 1, section 5); for dis-
ease activity the BVAS (version 3) [26] is used and for
damage the Vasculitis Damage Index (VDI) [27] (Fig. 1,
section 6). The disease evolution is presented in the
form of graphics and charts and includes all measure-
ments available during visits for erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), creatinine,
eosinophil count, BVAS, VDI and ANCA titres (Fig. 1,
section 7).
Fig. 1 Brief summary of the Reuma.pt/vasculitis contents. ACR American College of Rheumatology, AHA American Heart Association, ANCA anti-
neutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, CNS Central Nervous System, CRP C-reactive protein, eGFR (MDRD)
estimated glomerular filtration rate by the modification of diet in renal disease study equation, EGPA eosinophilic granulomatosis with
polyangiitis, ELISA Enzyme-Linked Immunosorbent Assay, EQ-5D EuroQol-5D, ESR erythrocyte sedimentation rate, FACIT Functional Assessment of
Chronic Illness Therapy Fatigue Scale, FFS Five Factor Score, GBM glomerular basement membrane, GPA granulomatosis with polyangiitis, HADS
Hospital Anxiety and Depression Scale, HLA human leukocyte antigen, ICBD International Criteria for Behçet’s disease, IF immunofluorescence, ISG
International Study Group, MPO myeloperoxidase, PR3 Proteinase 3, SF-36 Short form 36, UNK unknown, VDI Vasculitis Damage Index
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Eligibility
Eligible patients include all patients with a diagnosis of
vasculitis. Although the structure of Reuma.pt/vasculitis
is currently better suited to collect data from adult pa-
tients, we are also including patients aged below 18
years. A specific module for Paediatric vasculitis, includ-
ing the EULAR/PRINTO/PRES criteria [28] and disease
specific assessment scores (for e.g. the Paediatric Vascu-
litis Activity Score [29] and the Paediatric Vasculitis
Damage Index [30]), is presently being developed. It will
work as a “sub-module” within the general Reuma.pt/
vasculitis protocol, into which all paediatric vasculitic
patients will “migrate” after being operational. Of inter-
est, Reuma.pt currently has modules for Juvenile Idio-
pathic Arthritis and other Paediatric rheumatic
conditions and so has already extensive functionalities
applied to Paediatric rheumatology. In addition, patients
with vasculitis secondary to a connective tissue disease
are not included in Reuma.pt/vasculitis if their main
diagnosis is a disease that already has a Reuma.pt spe-
cific module (e.g. systemic lupus erythematosus,
rheumatoid arthritis and Sjögren’s syndrome). In those
cases, the clinical feature “vasculitis” is available for se-
lection in the different modules, allowing future identifi-
cation and easy extraction of data if needed. However,
only patients registered in Reuma.pt/vasculitis could be
evaluated using vasculitis specific assessment tools such
as BVAS or VDI. Patients can be registered either at dis-
ease presentation or during follow-up, in which case
data related to disease onset was registered
retrospectively.
Implementation and recruitment
All centres that work with Reuma.pt are allowed to
register patients into Reuma.pt/vasculitis. Before its offi-
cial launch, all Portuguese Rheumatology centres were
invited to participate in the active registry of patients
with vasculitis under the care of their department. On
the 31st of January 2015, a vasculitis workshop was held
in which the first results were presented and strategies
to improve the registry of patients were discussed.
Training and certification in performing BVAS and VDI
was also given at the workshop to ensure correct collec-
tion of prospective data.
Analysis
We analysed all patients registered in Reuma.pt/vasculitis,
up to July 2018, with descriptive analysis of the demo-
graphics; number of visits per patient; disease duration;
diagnosis according to the Chapel Hill nomenclature; clas-
sification criteria of the two most common types of vascu-
litis registered; type of organ involvement; immunology
and genetics; imaging and biopsies results (when applic-
able); immunosuppressive treatment; adverse events;
disease specific assessment tools; patient reported out-
comes; and follow-up. Regarding the disease specific as-
sessment tools, we assessed the proportion of patients
with AAV and PAN who had a FFS of 0, 1 and ≥ 2, and
calculated the median and interquartile range (IQR) BVAS
at first visit and VDI at last visit for patients with the most
common small- and medium-vessel vasculitides recorded.
Differences in median BVAS and VDI between vasculit-
ides were compared using Mann Whitney U tests. Patients
who had longitudinal data on BVAS recorded, were
assessed for the occurrence of any relapses (BVAS ≥1) as
well as for major relapses (≥1 major BVAS item) [31]. The
number of patients who relapsed within each subtype of
vasculitis was compared using chi-square analyses. An ad-
justed Cox proportional hazard model was used to identify
variables affecting survival. Statistical significance was set
at p < 0.05.
Results
General data
A total of 687 patients from 13 different Portuguese cen-
tres were registered into Reuma.pt/vasculitis. The num-
ber of participating centres increased with time, but
around half the patients registered came from an unique
centre that has a dedicated vasculitis outpatient clinic
[32]. Data was prospectively collected at each visit and
in total there were 1945 visits registered (2.8 visits/pa-
tient). The mean age was 53.4 ± 19.3 years at last visit;
68.7% were females. The diagnoses registered according
to the 2012 Chapel Hill Consensus nomenclature are
presented in Table 1. The main features of the most
common subtypes of vasculitis registered (n ≥ 20) are
presented in Table 2. A longer delay in diagnosis was
most commonly seen in patients with Behçet’s disease
(BD), with an average of 82.5 ± 110.1 (0–672) months
from disease onset to diagnosis (disease onset was com-
monly considered by the physicians as the first disease
manifestation attributable to vasculitis); the subtype of
vasculitis with less time taken to diagnose since disease
onset was GCA with an average of 4 ± 10.9 (0–84)
months.
Classification criteria and diagnostic modalities
The most common diagnoses were Behçet’s disease (BD)
(n = 298; 42.5%) and giant cell arteritis (GCA) (n = 125;
17.8%). All diagnoses recorded were based on physician’s
clinical judgement. For BD, 216 patients had enough
data to assess the International Study Group (ISG) 1990
criteria and for 251 patients, we could apply the Inter-
national Criteria for BD (ICBD) (most of the remaining
patients were lacking evidence of the results of the
pathergy test); 85.3% met the 1990 ISG criteria, 97.2%
the 2006 ICBD, and 97.2% the 2013 ICBD. HLA-B51
typing was available in around half the BD cases (n =
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131), with positive results in 45% (n = 59). For GCA, 118
patients had enough data to assess the 1990 American
College of Rheumatology classification criteria (most of
the remaining patients were lacking biopsy); 97.5% of
118 cases met the criteria. A biopsy of the temporal ar-
tery was performed in around half the cases (n = 72),
compatible with vasculitis in 65% (n = 47). Results for
ultrasound of the temporal ± axillary arteries were avail-
able in 94 cases, 87% showing a non-compressible halo
compatible with GCA (n = 82). A total of 52 patients
with the diagnosis of GCA undertook both exams: 56%
(n = 29) had positive biopsy and ultrasound; 21% (n = 11)
had positive ultrasound and negative biopsy; 8% (n = 4)
had positive biopsy and negative ultrasound; and 15%
(n = 8) had negative biopsy and ultrasound. Recently, a
tendency has been observed for performing ultrasound,
rather than biopsy, to diagnose patients with GCA, as
well as to complement the ultrasound assessment of
temporal arteries with the evaluation of axillary arteries.
Detailed description on axillary assessment was available
in 36/94 ultrasound reports, with 11/36 (30.5%) cases
compatible with large vessel-GCA (LV-GCA). Moreover,
a positron emission tomography (PET) was performed
to diagnose vasculitis in five patients, revealing LV-GCA
in all of them, a computed tomography angiography
(CTA) was performed in six patients, compatible with
LV-GCA in only two cases, and no patient with GCA
was reported to undergo magnetic resonance angiog-
raphy (MRA). In total, imaging assessment for large
vessel involvement of the disease was reported in 41/125
patients with GCA, 16/42 (38.1%) compatible with LV-
GCA. In TAK, 36 detailed imaging reports were avail-
able for 22/29 patients (79%) with this diagnosis. Results
were compatible with vasculitis in 16/16 CTAs, 8/12
PETs, 4/4 catheter-based dye angiograms, 3/3 ultra-
sounds, and 1/1 MRA. All 22 patients had at least one
imaging modality with reported vasculitis.
In other less common subtypes of vasculitis regis-
tered, particularly in small vessel vasculitis, the diag-
nosis was mostly based on immunology and biopsy
results. ANCA testing was available in 87.0% of pa-
tients with AAV and 80.8% of patients with PAN;
Table 2 shows respective ANCA status and subtype.
Biopsy results were available in 84.6, 58.5, 37.9 and
36.4% of patients with PAN, GPA, EGPA and MPA,
respectively. Table 3 shows the number of biopsies
obtained from different sites and percentage of cases
compatible with vasculitis. In patients with the diag-
nosis of cryoglobulinaemic vasculitis, the cryoglobu-
lins subtype was available in 60% of cases (n = 12):
type II was the most common subtype (58.3%),
followed by type I (25.0%) and type III (16.7%). In pa-
tients with associated hepatitis C infection, 80% were
type II (n = 4) and 20% were type I (n = 1).
Table 1 Diagnosis according the 2012 Revised International
Chapel Hill Consensus Conference Nomenclature of Vasculitides
Sub-type of vasculitis N (%)
Large vessel vasculitis
Takayasu’s arteritis 28 (4)
Giant cell arteritis 125 (17.8)
Non-classifiable large vessel vasculitis 10 (1.4)
Medium vessel vasculitis
Polyarteritis nodosab 26 (3.7)
Kawasaki disease 1 (0.1)
Non-classifiable medium vessel vasculitis 2 (0.3)
Small vessel vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Microscopic polyangiitis 22 (3.1)
Granulomatosis with polyangiitis 41 (5.8)
Eosinophilic granulomatosis with polyangiitis 29 (4.1)
Non-classifiable ANCA-associated vasculitis 11 (1.6)
Immune complex small vessel vasculitis
Cryoglobulinaemic vasculitis 20 (2.9)
IgA vasculitis 16 (2.3)
Variable vessel vasculitis
Behçet’s disease 298 (42.5)
Cogan’s syndrome 12 (1.7)
Single-organ vasculitis
Cutaneous leukocytoclastic angiitis 16 (2.3)
Cutaneous arteritisb 4 (0.6)
Primary central nervous system vasculitis 3 (0.4)
Other 10 (1.4)
Vasculitis associated with systemic disease
Rheumatoid vasculitis 2 (0.3)
Other 11 (1.6)
Vasculitis associated with probable etiology
Hepatitis C virus-associated cryoglobulinaemic vasculitis 5 (0.7)
Hepatitis B virus-associated vasculitis 1 (0.1)
Drug-associated immune complex vasculitis 1 (0.1)
Cancer-associated vasculitis 2 (0.3)
Other 5 (0.7)
TOTALa 701 (100)
a The number of diagnoses is higher than the number of patients, given
that in 14 cases more than one diagnosis was selected: six patients with
cryoglobulinaemic vasculitis and hepatitis C virus-associated
cryoglobulinaemic vasculitis (n = 5) or other vasculitis associated with
systemic disease (n = 1); three patients with cutaneous leukocytoclastic
angiitis and other vasculitis associated with systemic disease (n = 2) or
non-classifiable large vessel vasculitis (n = 1); two patients with single-
organ vasculitis and granulomatosis with polyangiitis (n = 1) or other
vasculitis associated with systemic disease (n = 1); two patients with other
vasculitis associated with systemic disease and polyarteritis nodosa (n =
1) or non-classifiable ANCA-associated vasculitis (n = 1); and one patient
with Takayasu‘s arteritis and Hepatitis B virus-associated vasculitis
bAll patients with polyarteritis nodosa had systemic involvement of the
disease; all patients with cutaneous arteritis had limited forms of
polyarteritis nodosa
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Table 2 Demographics, organ involvement, disease assessments and treatment of the most common subtypes of vasculitis
registered in Reuma.pt/vasculitis
TAK GCA PAN MPA GPA EGPA CV BD
Number of patients (N) 28 125 26 22 41 29 20 298
Demographics
Female/male ratio 6 1.8 0.9 3.4 1.6 2.2 4 3
Mean age at onset, years (SD) 32.1 74.4 40.4 59.8 47.6 48.1 57.8 27
(13.8) (8) (20.5) (12.5) (14.8) (16.3) (12.8) (12.7)
Mean age at diagnosis, years (SD) 34.5 74.7 42.5 60.7 50 51.7 58.7 33.8
(14.6) (7.8) (18.9) (12.3) (14.1) (14.9) (13.6) (12.1)
Mean age at last visit, years (SD) 40 77.6 55.8 62.3 56.4 57.6 59.4 43.9
(15.8) (7.9) (18.1) (15.2) (12.1) (15.5) (15.3) (14.9)
Organ involvement (%)
Constitutional symptoms 56.5 59.5 62.5 60.0 69.4 45.8 47.1 26.6
Musculoskeletal 34.8 60.7 79.2 70.0 65.7 54.2 76.5 60.2
Skin 4.5 1.7 75.0 30.0 47.2 60.0 75.0 74.3
Eyes 21.7 47.1 12.5 10.0 31.4 16.7 11.8 36.8
ENT 8.7 50.0 8.7 30.0 82.9 62.5 11.8 4.5
Chest / pulmonary 9.1 1.7 20.8 45.0 58.3 100 – 4.5
Cardiovascular 87.5 69.7 50.0 10.0 8.6 29.2 17.6 17.3
Gastrointestinal 29.2 4.9 20.8 20.0 17.1 16.7 11.8 98.5
Oral ulceration 4.2 – – 15.0 8.6 8.3 – 98.5
Other symptoms 25.0 4.9 20.8 5.0 8.6 8.3 11.8 16.4
Genitourinary 52.2 3.3 33.3 80.0 58.3 12.5 5.9 83.6
Genital ulceration 4.3 – – – – – – 83.6
Other symptoms 47.8 3.3 33.3 80.0 58.3 12.5 5.9 4.0
Neurologic 54.4 88.6 45.8 40.0 42.9 66.7 47.1 19.0
Diagnostic tests
c-ANCA or ANCA-PR3 positivity
N/N of patients (%)
0/14 0/36 0/21 4/21 26/36 3/23 0/15 0/93
(0.0) (0.0) (0.0) (19.0) (72.2) (13.0) (0.0) (0.0)
p-ANCA or ANCA-MPO positivity
N/N of patients (%)
0/14 0/36 0/21 16/21 6/36 10/23 0/15 1/92
(0.0) (0.0) (0.0) (76.2) (16.7) (43.5) (0.0) (1.1)
Vascular imaging with vasculitis a
N/N of patients (%)
22/22 85/95 4/5 −/− −/− −/− −/− 5/8
(100) (89.5) (80.0) (62.5)
Biopsy compatible with vasculitis b
N/N of patients (%)
2/3 47/72 16/22 6/8 7/21 6/11 1/1 −/−
(66.6) (65.3) (72.3) (75.0) (33.3) (54.5) (100)
Disease assessments
FFS 1996
N/N of patients (%)
FFS = 0 – – 16/23 7/20 – 17/23 – –
(69.6) (35.0) (73.9)
FFS = 1 5/23 5/20 6/23
(21.7) (25.0) (26.1)
FFS≥ 2 2/23 8/20 0/23
(8.7) (40.0) (0.0)
FFS 2011
N/N of patients (%)
FFS = 0 – – 18/23 6/20 18/36 10/24 – –
(78.3) (30.0) (50.0) (41.7)
FFS = 1 4/23 9/20 13/36 13/24
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Disease assessment, treatment, and follow-up
Disease assessment in patients with vasculitis targets
four main domains - activity, damage, prognosis and
quality of life - and it is based on the combination of
physical examination, laboratory biomarkers, imaging
modalities and assessment tools. In large-vessel vascu-
litis, given there are no specific monitoring tools, disease
assessment is mostly based on clinical symptoms, con-
ventional acute phase markers (erythrocyte sedimenta-
tion rate [ESR] and C-reactive protein [CRP]), and
imaging. A total of 63 ultrasounds were performed in 35
patients with an established diagnosis of GCA for moni-
toring purposes.
In small- and medium-vessel vasculitis disease activity
is assessed by BVAS and damage by VDI. Although high
BVAS and VDI scores have been associated with in-
creased mortality in these patients [33, 34], prognosis is
usually assessed using the FFS (FFS 1996 for MPA,
EGPA and PAN; and revised FFS 2009 for all AAV and
PAN, but not yet validated on non-French patients).
Table 2 shows a FFS of ≤1 for most of the AAV and
PAN, suggesting that most patients registered are
Table 2 Demographics, organ involvement, disease assessments and treatment of the most common subtypes of vasculitis
registered in Reuma.pt/vasculitis (Continued)
TAK GCA PAN MPA GPA EGPA CV BD
(17.4) (45.0) (36.1) (54.2)
FFS≥ 2 1/23 5/20 5/36 1/24
(4.3) (25.0) (13.9) (4.1)
Median BVAS v3 at first visit (IQR) – – 12.0 17.5 17.0 15.0 8.0 –
(6.0) (9.0) (15.5) (12.0) (10.5)
Median VDI at first visit (IQR) – – 3.0 3.0 1.5 3.0 1.0 –
(3.0) (3.0) (2.8) (3.0) (3.0)
Treatment with DMARDs (%)
Synthetic DMARDs
Azathioprine 16.0 0.8 70.8 68.4 41.0 39.3 22.2 30.3
Colchicine – – – – . – 5.6 75.3
Cyclophosphamide oral – – 8.3 5.3 23.1 – 5.6 0.8
Cyclophosphamide IV 16.0 0.8 41.7 42.1 41.0 17.9 11.1 5.2
Cyclosporine – – – 5.3 2.6 – 16.7 12.7
Hydroxychloroquine – – 4.2 – 5.1 – 16.7 2.0
Leflunomide – – – – – – 5.6 –
Methotrexate 64.0 36.1 33.3 10.5 43.6 17.9 16.7 10.0
Mycophenolate mofetil – – 8.3 21.1 5.1 3.6 5.6 0.8
Sulfasalazine – – – – – – – 4.8
Biological DMARDs
Adalimumab – – – – – – – 2.4
Etanercept – – – – – – – 1.2
Infliximab 4.0 – 8.3 – – – – 5.6
Mepolizumab – – – – – 3.6 – –
Rituximab – – 8.3 26.3 41.0 3.6 16.7 –
Tocilizumab 12.0 0.8 – – – – – 0.4
ANCA Anti-neutrophil cytoplasmic antibody, BD Behçet’s disease, BVAS v3 Birmingham Vasculitis Activity Score version 3, c-ANCA Cytoplasmic ANCA:CV
Cryoglobulinaemic vasculitis, DMARDs Disease-modifying anti-rheumatic drugs, EGPA Eosinophilic granulomatosis with polyangiitis, ENT Ear nose and throat, FFS
Five Factor Score, GCA Giant cell arteritis, GPA Granulomatosis with polyangiitis, IQR Interquartile range, IV Intravenous, LVV Large vessel vasculitis, MPA
Microscopic polyangiitis, MPO Myeloperoxidase, PAN Polyarteritis nodosa, p-ANCA Perinuclear ANCA, PR3 Proteinase 3, SD Standard deviation, TAK Takayasu’s
arteritis, VDI Vasculitis Damage Index
aIn LVV, ultrasound showing halo sign, angiography showing vascular wall thickening, enhancement, stenosis, occlusion, or aneurysms, or PET showing FDG
uptake of the aorta or its major branches. In PAN, angiography showing multiple microaneurysms. In BD, angiography showing thrombosis, vascular wall
thickening, enhancement, stenosis, occlusion, or aneurysms
bIn LVV, presence of arteritis, often granulomatous, affecting the aorta or its major branches. In PAN, necrotizing arteritis of medium or small arteries. In AAV,
necrotizing vasculitis predominantly affecting small vessels: in EGPA eosinophil-rich and necrotizing granulomatous inflammation, in GPA necrotizing
granulomatous inflammation, and in MPA necrotizing inflammation with absence of granulomas. In CV, vasculitis affecting small vessels with cryoglobulin
immune deposits
Ponte et al. Orphanet Journal of Rare Diseases          (2020) 15:110 Page 7 of 12
expected to have a good chance of survival at 5 years.
Disease activity at first evaluation was higher in patients
with AAV, with a median [IQR] BVAS of 17.0 [12.0], in
comparison to PAN (BVAS 12.0 [6.0]; p = 0.025) and
cryoglobulinaemic vasculitis (BVAS 8.0 [10.5]; p = 0.002).
There were no differences in cumulative damage at last
visit between patients with AAV and PAN (median
[IQR] VDI 2.0 [3.0] vs. 3.0 [3.0], p = 0.847); however, me-
dian [IQR] VDI of patients with cryoglobulinaemic vas-
culitis (1.0 [3.0]) was significantly lower in comparison
to PAN (p = 0.001) and AAV (p < 0.001). In addition, no
differences in disease activity at first visit and cumulative
damage at last assessment were found amongst each
subtype of AAV (p > 0.05). Prospective BVAS assessment
was available for 12 patients with PAN (collected in 74
visits), 36 patients with AAV (collected in 125 visits) and
2 patients with CV (collected in 5 visits). In PAN, 6/12
(50%) patients had at least one disease relapse recorded
(1/6 with a major relapse), in AAV, 18/36 (50%) patients
had at least one relapse recorded (7/18 with a major re-
lapse); and in CV, 1/2 (50%) patients had at least one re-
lapse recorded (corresponding to a major relapse). No
differences were found in the proportion of patients with
a diagnosis of PAN or AAV who relapsed (p = 1.00) or
had a major relapse (p = 0.479). Moreover, amongst each
subtype of AAV, there were no differences found in the
number of patients who relapsed (MPA 4/10, GPA 8/17,
and EGPA 6/9; p > 0.05) or who had a major disease re-
lapse (MPA 2/4, GPA 2/8, and EGPA 2/6; p > 0.05). In
all vasculitides quality of life has been assessed by gen-
eric measures such as the SF-36, currently included in
the AAV core set measures of assessment endorsed by
the Outcome Measures in Rheumatology (OMERACT)
Vasculitis Working Group [35] and used in trials of
large-vessel vasculitis (LVV) [36]. However, the rate of
its completion in Reuma.pt/vasculitis was very low; only
9.6% (n = 66) of patients had at least one SF-36 com-
pleted in the evaluation of their disease (total of 97
visits), most commonly assessed in BD (n = 55), followed
by AAV (n = 4) and LVV (n = 4). Other patient reported
outcomes were also evaluated in less then 10% of pa-
tients: 67 patients (9.8%) completed FACIT in 89 visits;
64 patients (9.3%) completed HADS in 87 visits; and 43
patients (6.3%) completed EQ-5D in 69 visits.
Data on treatment with disease-modifying antirheu-
matic drugs (DMARDs) for the most common vasculit-
ides registered is detailed in Table 2. A total of 59
biologic DMARDs, most frequently rituximab (n = 27;
45.7%), were prescribed for 53 patients. The following
proportion of patients within each subtype of vasculitis,
in whom detailed therapy was registered, were treated
with biologic DMARDs: 4/25 (16.0%) patients with TAK;
1/122 (0.8%) patients with GCA; 3/24 (12.5%) patients
with PAN; 5/19 (26.3%) patients with MPA; 16/39
(41.0%) patients with GPA; 2/28 (7.1%) patients with
EGPA; 3/18 (16.7%) patients with CV; and 19/251 (7.6%)
with BD. Moreover, 77 adverse advents related to treat-
ment (in around ¼ of cases considered severe) were re-
ported in 53 patients, most commonly due to
prednisolone (n = 18; 23%), followed by methotrexate
(n = 15; 19%) and azathioprine (n = 10; 13%).
Deaths were reported in 34 (4.9%) patients (20 females
and 14 males), at a mean age of 72.6 ± 15.5 [30–98] years
and mean disease duration of 4.9 ± 5.7 [0–22] years;
however, specific cause of death was available in only 10
cases, none of which directly related to treatment. Infec-
tion was the most common cause of death (n = 4; re-
spiratory infection in three cases and urosepsis in one
case), followed by cardiovascular events (n = 3; stroke,
heart attack, and pulmonary embolism), complications
of the disease (n = 2; ischaemic colitis in a patient with
PAN and complication of an aortic aneurysm surgery in
a patient with TAK) and acute kidney injury (n = 1).
Deaths were most commonly reported in patients with
the diagnosis of GCA (n = 11), followed by AAV (n = 6),
CV (n = 5), PAN (n = 2), TAK (n = 2), BD (n = 2), and
Table 3 Biopsies compatible with vasculitis performed in patients with the diagnosis of polyarteritis nodosa or ANCA-associated
vasculitides per site of involvement
PAN GPA EGPA MPA
Patients who underwent biopsy (N) 22 21 11 8
Positive biopsies per sitea (N/N total performed) (%)
• Ear, nose and throat (ENT) – 2/12 (16.7) 1/3 (33.3) 1/3 (33.3)
• Kidney – 3/8 (37.5) – 6/8 (75.0)
• Lung – 0/6 (0.0) 1/2 (50.0) –
• Skin 13/16 (81.3) 1/2 (50.0) 3/8 (37.5) –
• Peripheral nerve 1/1 (100) 1/3 (33.3) 2/2 (100) 2/2 (100)
• Intestine 1/1 (100) – – –
• Other 2/7 (28.6) 0/1 (0.0) 0/1 (0.0) –
a Compatible with vasculitis
EGPA Eosinophilic granulomatosis with polyangiitis, GPA Granulomatosis with polyangiitis, MPA Microscopic polyangiitis, PAN Polyarteritis nodosa
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other subtypes of vasculitis (n = 6). However, an adjusted
Cox proportional hazard model for age and sex, demon-
strated that there was no statistically significant difference
in terms of survival between patients with the diagnosis of
GCA and other vasculitides (HR 0.53, 95% CI: 0.21–1.36),
and AAV and other vasculitides (HR 1.08, 95% CI: 0.42–
2.79). Patients with AAV who underwent biologic
DMARDs presented an increased rate of 5-year mortality
(HR 16.44, 95% CI 1.71–157.65), but no differences in sur-
vival were found between AAV patients with a FFS of 0
and a FFS of ≥1 (1996 FFS: HR 5.51, 95% CI 0.22–140.17;
2009 FFS: HR 0.69, 95% CI 0.42–11.29). There were three
patients discharged from hospital care into general prac-
tice due to disease remission (GCA [n = 1], BD [n = 1],
and cutaneous leukocytoclastic angiitis [n = 1]) and 43
cases of lost to follow-up (most frequently in patients with
BD [n = 17] and GCA [n = 8]).
Discussion
Reuma.pt/vasculitis is an efficient electronic clinical rec-
ord and online registry for patients with the diagnosis of
vasculitis, designed to record all relevant data in clinical
practice following a standardised approach. It provides
an opportunity to improve the quality of clinical care in
this group of rare diseases and characterize the natural
history of vasculitis captured by different Portuguese
Rheumatology centres.
Reuma.pt/vasculitis works as a data repository at a na-
tional level with the potential to link with other inter-
national databases. To our knowledge, there are eight
other European countries with an established vasculitis
registry: United Kingdom and Ireland (UKIVAS) [6, 37];
France (FVSG registry) [38]; Spain (REVAS) [39]; Poland
(POLVAS registry) [7, 40]; Norway (NorVas) [41]; Czech
Republic (Czech Registry of AAV) [42]; and Greece
(Greek Registry of AAV) [43]. In addition, in many other
European countries the development of a vasculitis
registry is on their research agendas (e.g. Germany,
Switzerland, the Netherlands and Italy) [8]. Reuma.pt/
vasculitis was developed based on local expertise and
adaptions from other pre-existing European registries
(mainly UKIVAS) and the DCVAS CRF (the largest
international study in vasculitis) [22]. Therefore, it al-
lows for compatible future joint exports as part of the
EUVAS long-term strategy of aligning the European vas-
culitis registries and establish agreed core-set items
present in all registries [8]. This capability is also an es-
sential requirement of the current European Reference
Network initiative to improve care for patients with rare
diseases, including vasculitis [44].
Reuma.pt/vasculitis comprises a group of various sub-
types of vasculitis, with different clinical manifestations,
classification criteria and disease specific assessments
and outcomes of interest. In addition, the registry of data
by the physicians is done on an entirely voluntary basis.
Therefore, balancing granularity and feasibility of data
collection, when constructing the database, posed a chal-
lenge. Although we encountered missing data in our
analysis, mainly on the prospective disease assessments
and cause of death, overall our data was robust and
allowed us to obtain reliable information on many of our
patients’ characteristics. More than 1/3 of patients had
the diagnosis of BD (n = 298), largely followed by GCA
(n = 125). Although Reuma.pt/vasculitis is a registry
reflecting the reality of the Portuguese Rheumatology
centres and is generally not intended for epidemiologic
studies, the number of patients with BD registered
(97.2% and 85.3% fulfilling the ICBD and the ISG cri-
teria, respectively) exceeded the previously reported
prevalence of 1.5 per 100,000 in 1991 [45] and of 2.4 per
100,000 in 1997 [46], highlighting the need for new epi-
demiologic studies on this disease in Portugal. Another
interesting fact is that there were more patients diag-
nosed with GCA that undertook ultrasound in compari-
son to TAB (n = 94 vs. n = 72), reflecting modern
practice and the incorporation of ultrasound as an es-
sential diagnostic tool in the Rheumatology setting [47].
The immunosuppressive treatment used in these pa-
tients is in line with current European League Against
Rheumatism (EULAR) recommendations for the man-
agement of AAV, LVV and BD [48–50]; the fact that
only one patient with GCA (0.8%) was treated with toci-
lizumab reflects the low national accessibility to this
DMARD in the context of this indication, which is ex-
pected to change in the near future.
There were some limitations found in Reuma.pt/vas-
culitis. Besides the expected missing data and underre-
porting (e.g. imaging results in LVV and PAN, biopsy
results and ANCA status in AAV, detailed treatment,
etc.), very frequently encountered in this sort of registry,
the diagnosis of each subtype of vasculitis was purely
based on the submitting physician’s clinical knowledge
and experience, therefore lacking external validation. In
addition, most of the classification criteria used are cur-
rently outdated and waiting for the DCVAS results to
ensure proper update [22]. Moreover, not all physicians
who registered patients are either certified on the BVAS
and VDI assessments, or have proper practice in evaluat-
ing patients with vasculitis using these assessment tools.
Although we provided initial training we recommend
more practice and certification sessions in the future to
guarantee data quality and correct assessment of disease
activity and damage, particularly in patients under bio-
logic DMARDs.
We expect this registry to continue expanding, includ-
ing more centres, different specialties (e.g. Nephrology)
and other data items. We aim to include the new AAV
patient-reported outcomes (AAV-PRO) [51]; a specific
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module for Paediatric patients; and potentially divide the
registry into a basic dataset (with mandatory collection
of data), intermediate dataset (to include more advanced
fields on the dataset, such as patient reported outcomes)
and advanced dataset (used for specific trials and clinical
studies), therefore increasing the feasibility of data col-
lection and reducing the inherit missing data.
Conclusion
We anticipate that Reuma.pt/vasculitis will form the basis
of many future national and international studies of vascu-
litis by allowing recruitment into trials, benchmarking and
service planning. Its link to the biobank will facilitate trans-
lational research, and its connection to INFARMED will
ensure proper report of adverse effects related to treatment.
In addition, Reuma.pt/vasculitis will be an important source
for longitudinal observational studies on the most relevant
outcome measures of interest in vasculitis (e.g. treatment
efficacy).
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